Results 211 to 220 of about 8,034,026 (305)

Cost-Effectiveness of Extracorporeal Photopheresis in Patients With Chronic Graft-vs-Host Disease. [PDF]

J Health Econ Outcomes Res
Peacock A, Dehle FC, Mesa Zapata OA, Gennari F, Williams MRI, Hamad N, Larsen S, Harrison SJ, Taylor C.   +8 more
europepmc   +1 more source

AI‐Driven Rational Design of Nanotherapeutics for Pancreatic Ductal Adenocarcinoma

Medicinal Research Reviews, EarlyView.
ABSTRACT Pancreatic ductal adenocarcinoma (PDAC) remains a formidable malignancy characterized by late diagnosis, high recurrence rates, and pronounced chemoresistance. While nanoparticle‐based drug delivery systems (NDDS) offer theoretical advantages over conventional therapies, their clinical translation in PDAC has been severely limited.
Seohyun Choo, Kaeun Chae, Jueun Lee, Inseon Kim, Seunghun S. Lee   +4 more
wiley   +1 more source

Ruxolitinib in steroid-refractory acute graft-vs-host disease: Japanese subgroup analysis of the randomized REACH2 trial. [PDF]

Int J Hematol
Teshima T, Onishi Y, Kato K, Taniguchi S, Miyamura K, Fukushima K, Kato J, Ishikawa T, Doki N, Nakamae H, Maeda Y, Inamoto Y, Okada M, Maki A, Shimada F, Tajima T, Wroclawska M, Zeiser R, Onizuka M.   +18 more
europepmc   +1 more source

Mesenchymal stem cells as cellular factories for targeted P2X7 blockade after traumatic brain injury

Neuroprotection, EarlyView.
This manuscript presents a novel therapeutic strategy using mesenchymal stem cells (MSCs) engineered as living drug factories to deliver a P2X7‐blocking nanobody for treatment of ischemic stroke. By combining targeted cellular delivery with sustained local immunomodulation, the approach aims to overcome key limitations of systemic biologic ...
Lucia Fadon‐Padilla, Chengyan Chu, Lorissa McDougall, Yajie Liang, Chinmoy Sarkar, Marta Lipinski, Tim Magnus, Miroslaw Janowski, Piotr Walczak   +8 more
wiley   +1 more source

Autologous Gastrointestinal Graft-vs-Host Disease in a Patient With Multiple Myeloma and Hematopoietic Stem Cell Transplantation. [PDF]

ACG Case Rep J
Raza H, Naffouj S, Guzman G, Shuja A.
europepmc   +1 more source

Attitudes Toward Prenatal Interventions in the Fanconi Anemia Community

Prenatal Diagnosis, EarlyView.
ABSTRACT Objective In‐utero cell and gene therapies may offer prenatal treatment options for inherited diseases. Preclinical data suggests in‐utero (IU) hematopoietic stem cell transplantation (HSCT) could prevent Fanconi anemia (FA) related bone marrow failure without genotoxic conditioning or immune suppression.
Tony Lum, Catherine Lee, Tippi MacKenzie, Billie Lianoglou, Agnieszka Czechowicz   +4 more
wiley   +1 more source

The Impact of FDA-Approved Novel Agents for Steroid-Refractory Chronic Graft vs. Host Disease on Treatment Patterns and Outcomes-A Single-Center Longitudinal Cohort Analysis. [PDF]

Cancers (Basel)
Fridberg G, Amit O, Karni C, Tshernichovsky D, Shasha D, Rouach V, Varssano D, Bar-Shai A, Goldberg I, Wasserman G, Avivi I, Ram R.   +11 more
europepmc   +1 more source

Long‐term outcomes of haploidentical hematopoietic stem cell transplantation with antithymocyte globulin–based myeloablative conditioning in pediatric refractory or relapsed non‐Hodgkin lymphoma

Pediatric Investigation, EarlyView.
Single‐center retrospective data showed that ATG‐based myeloablative haploidentical hematopoietic stem cell transplantation provides durable remission and favorable long‐term survival in children with refractory/relapsed non‐Hodgkin lymphoma, achieving high engraftment rates, low relapse incidence, and acceptable toxicity.
Chenguang Jia, Jie Zheng, Meng Yuan, Hongbo He, Yibo Fan, Bin Wang, Guanghua Zhu, Jun Yang, Yanhui Luo, Lixiao Cai, Pan Zhang, Yanlong Duan, Maoquan Qin   +12 more
wiley   +1 more source

Improving Outcomes in Chronic Graft-vs-Host Disease. [PDF]

JAMA Dermatol
Mitchell SA, Cowen EW.
europepmc   +1 more source